Insider Selling: AnaptysBio (NASDAQ:ANAB) Insider Sells $460,000.00 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Eric Loumeau sold 10,000 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $46.00, for a total value of $460,000.00. Following the transaction, the insider directly owned 9,088 shares in the company, valued at $418,048. The trade was a 52.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

AnaptysBio Price Performance

Shares of NASDAQ ANAB opened at $49.08 on Friday. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $49.90. The business’s 50-day moving average price is $38.80 and its two-hundred day moving average price is $28.96. The company has a market capitalization of $1.36 billion, a P/E ratio of -17.40 and a beta of 0.29.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, topping the consensus estimate of ($1.06) by $1.58. The firm had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. On average, equities analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its Board of Directors has approved a stock repurchase program on Friday, November 21st that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the biotechnology company to purchase up to 9.6% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Trending Headlines about AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Guggenheim sharply raised its price target to $140 from $100, signaling strong analyst confidence in AnaptysBio’s pipeline and upside potential—this is a major bullish catalyst that can attract buyers and momentum investors. Guggenheim target raise
• Positive Sentiment: Recent company fundamentals support a stronger valuation: AnaptysBio reported a large revenue beat and positive quarterly EPS last quarter and the board has authorized a $100M buyback (up to ~9.6% of shares), both of which are supportive of higher share prices and institutional interest. MarketBeat company summary
• Neutral Sentiment: Institutional activity is mixed but constructive: some funds increased positions in Q3 while others adjusted exposure—this shows active interest but not a clear one-way flow. Monitor 13F updates for directional confirmation. Institutional holdings
• Negative Sentiment: CFO Dennis Mulroy sold 15,725 shares (~$705k) in mid‑December, reducing his stake by ~62.6%—a large, recent insider sale that can raise investor concern about near‑term insider sentiment. CFO Form 4
• Negative Sentiment: Executive Eric J. Loumeau completed multiple sales (10,000 and other tranches totaling sizable reductions), cutting his position by ~50–60% in filings—additional insider selling increases short‑term downside risk and can sap sentiment. Insider trades alert Loumeau Form 4
• Negative Sentiment: Barclays lowered its price target to $55 from $70 on Dec. 17, which is a modest negative signal that may temper enthusiasm from other bullish research. Barclays target cut

Institutional Investors Weigh In On AnaptysBio

A number of institutional investors and hedge funds have recently modified their holdings of ANAB. Larson Financial Group LLC boosted its holdings in shares of AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 473 shares during the period. Bessemer Group Inc. boosted its stake in shares of AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 1,292 shares during the period. US Bancorp DE raised its holdings in AnaptysBio by 126.5% in the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 979 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,377 shares during the period. Finally, Osaic Holdings Inc. grew its holdings in shares of AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares in the last quarter.

Wall Street Analyst Weigh In

ANAB has been the topic of a number of analyst reports. Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a research report on Thursday. Barclays dropped their target price on shares of AnaptysBio from $70.00 to $55.00 and set an “overweight” rating for the company in a research report on Wednesday. Wedbush restated an “outperform” rating and issued a $50.00 price target on shares of AnaptysBio in a research report on Monday, November 24th. HC Wainwright dropped their price objective on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating for the company in a research report on Monday, November 24th. Finally, Wells Fargo & Company increased their price target on AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, AnaptysBio currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.40.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.